Drug firm Lupin today said it has received approval from the US health regulator to market in America its Tetrabenazine tablets used for treatment of involuntary movements associated with Huntington's disease.
The company has received final approval to market the 12.5 mg and 25 mg tablets from the United States Food and Drug Administration (USFDA), Lupin said in a filing to BSE.
The tablets are generic versions of Valeant Pharmaceuticals North America LLC's Xenazine tablets in the same strengths, it added.
As per IQVIA MAT Jan 2018 data, Tetrabenazine tablets, 12.5 mg and 25 mg had annual sales of around USD 288.1 million in the US, Lupin said.
The product is indicated for the treatment of chorea associated with Huntington's disease, it added.
Shares of Lupin Ltd were trading at Rs 808.80 per scrip on BSE, up 1.31 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app